0001564590-20-032962.txt : 20200722 0001564590-20-032962.hdr.sgml : 20200722 20200721180705 ACCESSION NUMBER: 0001564590-20-032962 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20200721 FILED AS OF DATE: 20200722 DATE AS OF CHANGE: 20200721 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Liminal BioSciences Inc. CENTRAL INDEX KEY: 0001351172 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39131 FILM NUMBER: 201039756 BUSINESS ADDRESS: STREET 1: 440 BOULEVARD ARMAND STREET 2: FRAPPIER #300 CITY: LAVAL STATE: A8 ZIP: H7V 4B4 BUSINESS PHONE: 514-341-2115 MAIL ADDRESS: STREET 1: 440 BOULEVARD ARMAND STREET 2: FRAPPIER #300 CITY: LAVAL STATE: A8 ZIP: H7V 4B4 FORMER COMPANY: FORMER CONFORMED NAME: ProMetic Life Sciences Inc DATE OF NAME CHANGE: 20060126 6-K 1 lmnl-6k_20200716.htm 6-K lmnl-6k_20200716.htm

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of July 2020

 

Commission File Number: 001-39131

 

LIMINAL BIOSCIENCES INC.

(Translation of registrant’s name into English)

 

 

440 Armand-Frappier Boulevard, Suite 300

Laval, Québec

H7V 4B4

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:  

☒ Form 20-F   ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 


INCORPORATION BY REFERENCE

 

Exhibits 99.1 and 99.2 are hereby expressly incorporated by reference into the registrant’s registration statement on Form S-8 filed with the Securities and Exchange Commission on December 23, 2019 (File no. 333-235692).

 

EXHIBIT LIST

 

 

 


 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liminal BioSciences Inc.

 

 

 

 

Date: July 21, 2020

 

 

 

By:

 

/s/ Kenneth Galbraith

 

 

 

 

 

 

Name

 

Kenneth Galbraith

 

 

 

 

 

 

Title:

 

Chief Executive Officer

 

 

 

 

 

 

 EX-99.1 2 lmnl-ex991_8.htm EX-99.1 lmnl-ex991_8.htm

 

EXHIBIT 99.1

Press Release

For immediate release

 

Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven Diseases

 

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – July 17, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company, announced today that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals Inc. (“Fairhaven”), thus acquiring a preclinical research program of small molecule antagonists. Investigational therapies developed in this program target a key chemoattractant and activator of eosinophils, which play a key role in Type 2 inflammation-driven diseases through tissue repair and resolution of inflammation (“Fairhaven R&D Program”).

 

“This acquisition is a continuation and expansion of our strategy to build a diverse portfolio of early-stage R&D programs that complement our established research focus and our lead development opportunities with Ryplazim® and fezagepras,” stated Kenneth Galbraith, Chief Executive Officer of Liminal BioSciences. “We are making progress on our selective GPR84 antagonist R&D program and we look forward to advancing the promising Fairhaven R&D Program in our laboratories at Liminal BioSciences, utilizing our extensive GPCR experience and supported by funding provided initially by certain Fairhaven shareholders.”

 

The Fairhaven R&D Program is based on the research of Dr. William Powell, Professor Emeritus in the Department of Medicine at McGill University, working in collaboration with Dr. Joshua Rokach of the Florida Institute of Technology (FIT). Drs. Powell and Rokach developed a series of potentially first-in-class, oral, selective OXE receptor antagonists against 5-oxo-ETE, one of the most potent human eosinophil chemoattractants. Migration of eosinophils to body sites including the lungs and intestines is mediated by eosinophil chemoattractants such as 5-oxo-ETE. Eosinophils play a key role in Type 2 inflammation-

1

Press Release for immediate release

 

 

 

driven diseases, including certain respiratory and gastro-intestinal diseases. Dr. Powell will serve as an advisor to Liminal BioSciences on the Fairhaven R&D Program.

Eosinophil-related diseases represent a significant area of unmet need in global health. Several biologics have been approved for the treatment of eosinophil-related diseases with combined drug sales in 2018 exceeding US$3 billion. In addition, a number of other biologics and small molecules are under active clinical development for eosinophilic-driven diseases, including antolimab (Allakos).

 

“Compared to biologics, small molecule OXE receptor antagonists offer a promising and potentially more cost-effective treatment option for eosinophilic-driven disorders,” stated Dr. Powell. “I am looking forward to working with Liminal BioSciences to continue development on this exciting R&D program initiated by work carried out at McGill University and FIT.”

 

”The 5-oxo-ETE research program was one of AmorChem's first university-based research investments and we are very pleased by the outcome of this transaction, which provides strong further affirmation of our investment strategy,” stated Elizabeth Douville, Founder and Managing Partner of AmorChem. “When the program was spun off into Fairhaven following a co-investment by Genesys Capital, the transaction represented the first important step in the evolution of our portfolio. With Liminal BioSciences' extensive expertise in small molecules and GPCR’s, we believe the 5-oxo-ETE research program is well positioned for future development.”  

 

“This transaction is a great reflection of the potential for emerging life sciences companies in Canada. We are pleased that the innovative platform developed at Fairhaven will advance under the stewardship of Liminal BioSciences, which has an outstanding management team and extensive experience in pre-clinical and clinical research,” said Jamie Stiff, Managing Director at Genesys Capital. “We look forward to watching the continued progress in advancing the 5-oxo-ETE program under their leadership in the months and years ahead.”

 

Terms of the Transaction

Under the terms of the acquisition, the Company will satisfy the aggregate purchase price of up to C$8 million by the issuance of common shares in the capital of Liminal BioSciences to the shareholders of Fairhaven, being Genesys Ventures III LP

2

Press Release for immediate release

 

 

 

(“Genesys”), AMORCHEM, LIMITED PARTNERSHIP (“AmorChem LP”), MSBi Valorisation Inc. and The Royal Institution for the Advancement of Learning/McGill University subject to the achievement of certain pre-determined milestones. On the closing date of the acquisition, the Company issued an aggregate of 202,308 common shares in the capital of Liminal, representing C$3.6 million of the aggregate purchase price, to the shareholders of Fairhaven, at a price per share equal to the five-trading day volume weighted average trading price (the "VWAP") of Liminal BioSciences' common shares on the Toronto Stock Exchange (the "TSX"). The remainder of the aggregate purchase price payable by the Company to the sellers is issuable upon, and subject to, achievement of certain pre-determined research and development milestones, with any future shares to be issued at a price per share equal to the five-trading day VWAP of Liminal BioSciences' common shares prior to such milestone events.

 

In addition, in connection with the acquisition, Liminal BioSciences also completed a private placement with Genesys, AmorChem LP and AmorChem II Fund L.P. (together with AmorChem LP, “AmorChem”, and together with Genesys, the “Holders”) of C$2.4 million aggregate principal amount of secured convertible debentures (the "Debentures"), with an interest rate of 8% per annum, compounded quarterly, for the continued development of the Fairhaven R&D Program. The Debentures mature on March 31, 2022 (the “Maturity Date”), unless converted into common shares of the Company prior to the Maturity Date. At any time prior to the Maturity Date, the Holders shall have a collective right to, and Liminal BioSciences shall have the right upon certain pre-determined events to require each Holder to, purchase additional Debentures for an aggregate principal amount of up to C$5.74 million. The Debentures may be converted into common shares of Liminal BioSciences at the option of the Company subject to certain conditions, or at the option of the Holders at any time on, or before the Maturity Date, at a conversion price equal to the five-trading day VWAP of Liminal BioSciences' common shares on the TSX prior to the conversion date.

 

About Liminal BioSciences Inc.

Liminal BioSciences is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including respiratory, liver and kidney diseases that have high unmet medical need. Liminal BioSciences has a deep understanding of certain

3

Press Release for immediate release

 

 

 

biological targets and pathways that have been implicated in the fibrotic process, including fatty acid receptors such as FFAR1, or GPR40, G-protein-coupled receptor 84, or GPR84, and peroxisome proliferator-activated receptors, or PPARs. Our lead small molecule product candidate, fezagepras (PBI-4050), is expected to enter an additional Phase 1 clinical trial in 2H-2020 to evaluate multiple ascending doses of fezagepras in both healthy volunteers and patients, at daily dose exposures higher than those evaluated in our previously completed Phase 2 clinical trials. The optimal dose and dosing regimen of fezagepras is expected to be further evaluated in Phase 2 clinical trials in selected fibrosis indications to be initiated in 2021.

 

Liminal BioSciences has also leveraged its experience in bioseparation technologies through its subsidiary Prometic Bioproduction Inc. to isolate and purify biopharmaceuticals from human plasma. Our lead plasma-derived product candidate is Ryplazim® (plasminogen), for which the Company expects to resubmit a BLA in Q3-2020 with the FDA seeking approval to treat patients with congenital plasminogen deficiency. Ryplazim® (plasminogen) has been granted Orphan Drug Designation and Rare Pediatric Disease Designation by the FDA for the treatment of congenital plasminogen deficiency.

 

Prometic Plasma Resources, a subsidiary of Liminal BioSciences Inc., has joined the CoVIg-19 Plasma Alliance to contribute to the acceleration of the development of a potential new therapy for COVID-19. Our Canadian center located in Winnipeg, Manitoba is licensed by the FDA and Health Canada, and is certified by the European Union and the Plasma Protein Therapeutics Association (PPTA). Our American center located in Amherst, New York is licensed by the State of New York and its’ BLA submission is currently under review by the FDA.

 

Liminal BioSciences has active business operations in Canada, the United Kingdom and the United States.

 

About Amorchem

AmorChem (www.amorchem.com) is a leading early stage venture capital fund launched in 2011 in Montreal. The AmorChem team utilizes its deep understanding of fundamental science to uncover its therapeutic potential and focuses its core expertise in translational

4

Press Release for immediate release

 

 

 

research to accelerate therapeutic drug discovery and development across a broad spectrum of disease areas. The fund capitalizes on both its venture capital expertise and its entrepreneurial experience to spark the creation of start-up companies and help shape them into the next generation of biotech companies. With over $85M under management, AmorChem has financed over 30 university projects and started up several biotechnology companies from the fruits of this innovative research.

 

About Genesys Capital

Genesys Capital (www.genesyscapital.com) is one of the largest Canadian-based venture capital firms exclusively focused on the life sciences industry. For over 20 years, Genesys has been focused on building companies in the high-growth sectors of healthcare and biotechnology. Through its expertise and network, Genesys accelerates the development of commercially viable emerging companies that represent promising life sciences investment opportunities.

 

Forward Looking Statement

This press release contains forward-looking information within the meaning of securities laws. Specific forward‐looking information in this press release includes statements concerning, among other things, Liminal BioSciences’ objectives, strategies and businesses, the anticipated benefits of the acquisition and the private placement, the manner in which the Company expects to satisfy the remaining purchase price for the acquisition, the achievement of the milestone events and timing for the issuance of additional common shares, the issuance of additional Debentures, statements with respect to the timing of any planned BLA resubmission, development of R&D programs and the Fairhaven R&D Program, the timing of initiation of clinical trials, the exploration of alternatives for the future commercialization of Ryplazim®, if approved, including through a third-party marketing collaboration, and the potential commercial launch of Ryplazim®, if approved.

 

Forward-looking information is based on our current expectations about the markets we operate in and on various estimates and assumptions. Although the forward-looking information is based on information management believes to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such information.

5

Press Release for immediate release

 

 

 

 

Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. At this stage, the product candidates of the Company have not been authorized for sale in any country. The risks, and factors that could cause actual results to differ materially from those described or projected herein include, but are not limited to, Liminal BioSciences’ ability to develop, manufacture, and successfully commercialize product candidates if ever, the impact of the COVID-19 crisis on its business operations, clinical development, regulatory activities and financial and other corporate impacts, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical trials, the ability of Liminal BioSciences to take advantage of business opportunities in the pharmaceutical industry, uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals and general changes in economic conditions. You will find a more detailed assessment of these risks, uncertainties and other risks that could cause actual events or results to materially differ from our current expectations in the Company’s U.S. Securities and Exchange Commission and Canadian securities filings and reports available under the Company’s profile on SEDAR at www.sedar.com, including in the Annual Report on Form 20-F for the year ended December 31, 2019. As a result, we cannot guarantee that any forward-looking statement will materialize. Such risks may be amplified by the COVID-19 pandemic and its potential impact on Liminal BioSciences’ business and the global economy. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  We assume no obligation to update any forward-looking statement contained in this press release even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

 

For further information please contact:

 

Corporate Contact                           

Shrinal Inamdar

Manager, Investor Relations and Communications

s.inamdar@liminalbiosciences.com

6

Press Release for immediate release

 

 

 

+1 450.781.0115

 

Media Contact

Kaitlin Gallagher

kgallagher@berrypr.com

212.253.8881    

 

Investor Contact

Matt Lane

matt@gilmartinir.com

617.901.7698

7

Press Release for immediate release

 

 

 EX-99.2 3 lmnl-ex992_9.htm EX-99.2 lmnl-ex992_9.htm

 

EXHIBIT 99.2

Form 51-102F3
Material Change Report

Item 1 Name and Address of Company

Liminal BioSciences Inc. ("Liminal" or the "Company")

440 Armand-Frappier Blvd., Suite 300
Laval, QC, H7V 4B4

 

Item 2Date of Material Change

July 17, 2020

Item 3News Release

The press release attached as Schedule "A" was disseminated on July 17, 2020 on newswires in Canada and United States with respect to the material change and was filed on SEDAR.

Item 4Summary of Material Change

On July 17, 2020, the Company announced that it had acquired (the "Acquisition") all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals Inc. ("Fairhaven") and completed a concurrent private placement with each of Genesys Ventures III LP ("Genesys"), AMORCHEM, LIMITED PARTNERSHIP ("AmorChem LP") and AmorChem II Fund L.P. ("AmorChem II", and together with AmorChem LP, "AmorChem", and together with Genesys, the "Holders") of C$2.4 million aggregate principal amount of secured convertible debentures.

Item 5Full Description of Material Change

Under the terms of the Acquisition, the Company will satisfy the aggregate purchase price of up to C$8 million by the issuance of common shares in the capital of Liminal to the shareholders of Fairhaven, being Genesys, AmorChem LP, MSBi Valorisation Inc. and The Royal Institution for the Advancement of Learning/McGill University (collectively, the "Sellers") subject to the achievement of certain pre-determined milestones, thus acquiring a preclinical research program of small molecule antagonists. Investigational therapies developed in this program target a key chemoattractant and activator of eosinophils, which play a key role in Type 2 inflammation-driven diseases through tissue repair and resolution of inflammation ("Fairhaven R&D Program").

On July 17, 2020, the Company issued an aggregate of 202,308 common shares in the capital of Liminal, representing C$3.6 million of the aggregate purchase price, to the Sellers, at a price per share equal to the five-trading day volume weighted average trading price (the "VWAP") of Liminal's common shares on the Toronto Stock Exchange (the "TSX"). The remainder of the aggregate purchase price payable by the Company to the Sellers is issuable upon, and subject to, the achievement of certain pre-determined research and development milestones, with any future shares to be issued at a price per share equal to the five-trading day VWAP of Liminal's common shares prior to the achievement of such milestone events.

In addition, in connection with the Acquisition, Liminal also completed a concurrent private placement with the Holders of C$2.4 million aggregate principal amount of secured convertible debentures (the "Debentures"), with an interest rate of 8% per annum, compounded quarterly, for the continued development of the Fairhaven R&D Program. The Debentures will mature on March 31, 2022 (the "Maturity Date”), unless converted into common shares of the Company prior to the Maturity Date. At any time prior to the Maturity Date, the Holders shall have a collective right to, and Liminal shall have

 

- 2 -

the right upon certain pre-determined events to require each Holder to, purchase additional Debentures for an aggregate principal amount of up to C$5.74 million. The Debentures may be converted into common shares of Liminal at the option of the Company subject to certain conditions, or at the option of the Holders at any time on or before the Maturity Date, at a conversion price equal to the five-trading day VWAP of Liminal's common shares on the TSX prior to the conversion date.

The Acquisition constitute a "related party transaction" within the meaning of Regulation 61-101 – Protection of Minority Security Holders in Special Transactions ("Regulation 61-101"). The Company relied on the exemptions from the valuation and minority shareholder approval requirements contained in sections 5.5(a) and 5.7(1)(a) of Regulation 61-101 in respect of related party participation in the Acquisition, as neither the fair market value of the shares distributed to, nor the consideration paid by, related parties, exceeded 25% of the Company’s market capitalization.

Each of Mr. Kenneth Galbraith and Mr. Gary Bridger (the "Directors") serve on the board of directors of both Liminal and Fairhaven. In addition, the Directors are officers of, and owned all of the shares in the capital of, Five Corners Capital Inc., a former shareholder of Fairhaven immediately prior to the closing of the Acquisition. Pursuant to a corporate reorganization of Fairhaven which occurred prior to the closing of the Acquisition, Fairhaven repurchased all of the shares held by Five Corners Capital Inc. in the capital of Fairhaven, such that Five Corners Capital Inc. was no longer a shareholder of Fairhaven on the date of closing of the Acquisition. The independent directors of Liminal reviewed and unanimously approved the Acquisition.

Liminal did not file this material change report 21 days prior to completion of the Acquisition as the terms of the transactions had not been approved by all parties at that time and were subject to further amendment.

Item 6Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7Omitted Information

Not applicable.

Item 8Executive Officer

The following executive officer is knowledgeable about the material change and may be contacted about this report.

Marie Iskra

General Counsel

m.iskra@liminalbiosciences.com

+1 450.781.0115

 

Item 9Date of Report

July 21, 2020

 

 

Schedule A

Please see attached.

 


 

 

Press Release

For immediate release

 

Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven Diseases

 

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – July 17, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company, announced today that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals Inc. (“Fairhaven”), thus acquiring a preclinical research program of small molecule antagonists. Investigational therapies developed in this program target a key chemoattractant and activator of eosinophils, which play a key role in Type 2 inflammation-driven diseases through tissue repair and resolution of inflammation (“Fairhaven R&D Program”).

 

“This acquisition is a continuation and expansion of our strategy to build a diverse portfolio of early-stage R&D programs that complement our established research focus and our lead development opportunities with Ryplazim® and fezagepras,” stated Kenneth Galbraith, Chief Executive Officer of Liminal BioSciences. “We are making progress on our selective GPR84 antagonist R&D program and we look forward to advancing the promising Fairhaven R&D Program in our laboratories at Liminal BioSciences, utilizing our extensive GPCR experience and supported by funding provided initially by certain Fairhaven shareholders.”

 

The Fairhaven R&D Program is based on the research of Dr. William Powell, Professor Emeritus in the Department of Medicine at McGill University, working in collaboration with Dr. Joshua Rokach of the Florida Institute of Technology (FIT). Drs. Powell and Rokach developed a series of potentially first-in-class, oral, selective OXE receptor antagonists against 5-oxo-ETE, one of the most potent human eosinophil chemoattractants. Migration of eosinophils to body sites including the lungs and intestines is mediated by eosinophil chemoattractants such as 5-oxo-ETE. Eosinophils play a key role in Type 2 inflammation-driven diseases, including certain respiratory and gastro-intestinal diseases. Dr. Powell will serve as an advisor to Liminal BioSciences on the Fairhaven R&D Program.

1

Press Release for immediate release

 

Eosinophil-related diseases represent a significant area of unmet need in global health. Several biologics have been approved for the treatment of eosinophil-related diseases with combined drug sales in 2018 exceeding US$3 billion. In addition, a number of other biologics and small molecules are under active clinical development for eosinophilic-driven diseases, including antolimab (Allakos).

 

“Compared to biologics, small molecule OXE receptor antagonists offer a promising and potentially more cost-effective treatment option for eosinophilic-driven disorders,” stated Dr. Powell. “I am looking forward to working with Liminal BioSciences to continue development on this exciting R&D program initiated by work carried out at McGill University and FIT.”

 

”The 5-oxo-ETE research program was one of AmorChem's first university-based research investments and we are very pleased by the outcome of this transaction, which provides strong further affirmation of our investment strategy,” stated Elizabeth Douville, Founder and Managing Partner of AmorChem. “When the program was spun off into Fairhaven following a co-investment by Genesys Capital, the transaction represented the first important step in the evolution of our portfolio. With Liminal BioSciences' extensive expertise in small molecules and GPCR’s, we believe the 5-oxo-ETE research program is well positioned for future development.”  

 

“This transaction is a great reflection of the potential for emerging life sciences companies in Canada. We are pleased that the innovative platform developed at Fairhaven will advance under the stewardship of Liminal BioSciences, which has an outstanding management team and extensive experience in pre-clinical and clinical research,” said Jamie Stiff, Managing Director at Genesys Capital. “We look forward to watching the continued progress in advancing the 5-oxo-ETE program under their leadership in the months and years ahead.”

 

Terms of the Transaction

Under the terms of the acquisition, the Company will satisfy the aggregate purchase price of up to C$8 million by the issuance of common shares in the capital of Liminal BioSciences to the shareholders of Fairhaven, being Genesys Ventures III LP (“Genesys”), AMORCHEM, LIMITED PARTNERSHIP (“AmorChem LP”), MSBi Valorisation Inc. and The Royal Institution for the Advancement of Learning/McGill

2

Press Release for immediate release

 

University subject to the achievement of certain pre-determined milestones. On the closing date of the acquisition, the Company issued an aggregate of 202,308 common shares in the capital of Liminal, representing C$3.6 million of the aggregate purchase price, to the shareholders of Fairhaven, at a price per share equal to the five-trading day volume weighted average trading price (the "VWAP") of Liminal BioSciences' common shares on the Toronto Stock Exchange (the "TSX"). The remainder of the aggregate purchase price payable by the Company to the sellers is issuable upon, and subject to, achievement of certain pre-determined research and development milestones, with any future shares to be issued at a price per share equal to the five-trading day VWAP of Liminal BioSciences' common shares prior to such milestone events.

 

In addition, in connection with the acquisition, Liminal BioSciences also completed a private placement with Genesys, AmorChem LP and AmorChem II Fund L.P. (together with AmorChem LP, “AmorChem”, and together with Genesys, the “Holders”) of C$2.4 million aggregate principal amount of secured convertible debentures (the "Debentures"), with an interest rate of 8% per annum, compounded quarterly, for the continued development of the Fairhaven R&D Program. The Debentures mature on March 31, 2022 (the “Maturity Date”), unless converted into common shares of the Company prior to the Maturity Date. At any time prior to the Maturity Date, the Holders shall have a collective right to, and Liminal BioSciences shall have the right upon certain pre-determined events to require each Holder to, purchase additional Debentures for an aggregate principal amount of up to C$5.74 million. The Debentures may be converted into common shares of Liminal BioSciences at the option of the Company subject to certain conditions, or at the option of the Holders at any time on, or before the Maturity Date, at a conversion price equal to the five-trading day VWAP of Liminal BioSciences' common shares on the TSX prior to the conversion date.

 

About Liminal BioSciences Inc.

Liminal BioSciences is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including respiratory, liver and kidney diseases that have high unmet medical need. Liminal BioSciences has a deep understanding of certain biological targets and pathways that have been implicated in the fibrotic process, including fatty acid receptors such as FFAR1, or GPR40, G-protein-coupled

3

Press Release for immediate release

 

receptor 84, or GPR84, and peroxisome proliferator-activated receptors, or PPARs. Our lead small molecule product candidate, fezagepras (PBI-4050), is expected to enter an additional Phase 1 clinical trial in 2H-2020 to evaluate multiple ascending doses of fezagepras in both healthy volunteers and patients, at daily dose exposures higher than those evaluated in our previously completed Phase 2 clinical trials. The optimal dose and dosing regimen of fezagepras is expected to be further evaluated in Phase 2 clinical trials in selected fibrosis indications to be initiated in 2021.

 

Liminal BioSciences has also leveraged its experience in bioseparation technologies through its subsidiary Prometic Bioproduction Inc. to isolate and purify biopharmaceuticals from human plasma. Our lead plasma-derived product candidate is Ryplazim® (plasminogen), for which the Company expects to resubmit a BLA in Q3-2020 with the FDA seeking approval to treat patients with congenital plasminogen deficiency. Ryplazim® (plasminogen) has been granted Orphan Drug Designation and Rare Pediatric Disease Designation by the FDA for the treatment of congenital plasminogen deficiency.

 

Prometic Plasma Resources, a subsidiary of Liminal BioSciences Inc., has joined the CoVIg-19 Plasma Alliance to contribute to the acceleration of the development of a potential new therapy for COVID-19. Our Canadian center located in Winnipeg, Manitoba is licensed by the FDA and Health Canada, and is certified by the European Union and the Plasma Protein Therapeutics Association (PPTA). Our American center located in Amherst, New York is licensed by the State of New York and its’ BLA submission is currently under review by the FDA.

 

Liminal BioSciences has active business operations in Canada, the United Kingdom and the United States.

 

About Amorchem

AmorChem (www.amorchem.com) is a leading early stage venture capital fund launched in 2011 in Montreal. The AmorChem team utilizes its deep understanding of fundamental science to uncover its therapeutic potential and focuses its core expertise in translational research to accelerate therapeutic drug discovery and development across a broad spectrum of disease areas. The fund capitalizes on both its venture capital expertise and its

4

Press Release for immediate release

 

entrepreneurial experience to spark the creation of start-up companies and help shape them into the next generation of biotech companies. With over $85M under management, AmorChem has financed over 30 university projects and started up several biotechnology companies from the fruits of this innovative research.

 

About Genesys Capital

Genesys Capital (www.genesyscapital.com) is one of the largest Canadian-based venture capital firms exclusively focused on the life sciences industry. For over 20 years, Genesys has been focused on building companies in the high-growth sectors of healthcare and biotechnology. Through its expertise and network, Genesys accelerates the development of commercially viable emerging companies that represent promising life sciences investment opportunities.

 

Forward Looking Statement

This press release contains forward-looking information within the meaning of securities laws. Specific forward‐looking information in this press release includes statements concerning, among other things, Liminal BioSciences’ objectives, strategies and businesses, the anticipated benefits of the acquisition and the private placement, the manner in which the Company expects to satisfy the remaining purchase price for the acquisition, the achievement of the milestone events and timing for the issuance of additional common shares, the issuance of additional Debentures, statements with respect to the timing of any planned BLA resubmission, development of R&D programs and the Fairhaven R&D Program, the timing of initiation of clinical trials, the exploration of alternatives for the future commercialization of Ryplazim®, if approved, including through a third-party marketing collaboration, and the potential commercial launch of Ryplazim®, if approved.

 

Forward-looking information is based on our current expectations about the markets we operate in and on various estimates and assumptions. Although the forward-looking information is based on information management believes to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such information.

 

5

Press Release for immediate release

 

Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. At this stage, the product candidates of the Company have not been authorized for sale in any country. The risks, and factors that could cause actual results to differ materially from those described or projected herein include, but are not limited to, Liminal BioSciences’ ability to develop, manufacture, and successfully commercialize product candidates if ever, the impact of the COVID-19 crisis on its business operations, clinical development, regulatory activities and financial and other corporate impacts, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical trials, the ability of Liminal BioSciences to take advantage of business opportunities in the pharmaceutical industry, uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals and general changes in economic conditions. You will find a more detailed assessment of these risks, uncertainties and other risks that could cause actual events or results to materially differ from our current expectations in the Company’s U.S. Securities and Exchange Commission and Canadian securities filings and reports available under the Company’s profile on SEDAR at www.sedar.com, including in the Annual Report on Form 20-F for the year ended December 31, 2019. As a result, we cannot guarantee that any forward-looking statement will materialize. Such risks may be amplified by the COVID-19 pandemic and its potential impact on Liminal BioSciences’ business and the global economy. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  We assume no obligation to update any forward-looking statement contained in this press release even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

 

For further information please contact:

 

Corporate Contact                           

Shrinal Inamdar

Manager, Investor Relations and Communications

s.inamdar@liminalbiosciences.com

+1 450.781.0115

6

Press Release for immediate release

 

 

Media Contact

Kaitlin Gallagher

kgallagher@berrypr.com

212.253.8881    

 

Investor Contact

Matt Lane

matt@gilmartinir.com

617.901.7698

 

7

Press Release for immediate release

 GRAPHIC 4 grivwbx4srgo000001.jpg GRAPHIC begin 644 grivwbx4srgo000001.jpg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�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end GRAPHIC 5 g1ajumk05ua0000001.jpg GRAPHIC begin 644 g1ajumk05ua0000001.jpg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�!B M4444 >K:'(9=#LG/7R5'Y#']*OUD^&?^1=L_]T_^A&M:@#B?'G^OL?\ =?\ MF*Y"NO\ 'G^OL?\ =?\ F*Y"@ KV*'_41_[H_E7CM>Q0_P"HC_W1_*@!]%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %5K^\2PL9;F3D(N0/4]A^=6:X[QC?;IH;%#P@\Q_J>GZ?SJ9.R,ZL^2+ M9S<\[W,\DTK;I'8LQ]ZCHHKFY3R[W%HI**7*.XM;.E>'+K40LK_N+<]'89+? M0?UJ]X<\/"<)?7J?NNL<1'WO<^WMW^G7L:N%*^K.JC0NN:1FV>@Z=9 ;(!(X M_CE^8_X#\*TJ**Z%%+8[$DM$%%%%,84444 %%%% !1110 5S7BO5/)A%A$WS MR#,A'9?3\?Y?6MV^O(["SDN93\J#@>I["O-+FXDN[F2XE.9)&R37/7G9ERC6IN>%=+^TW1O91^Z MA/R>[_\ UO\ "NUJ"SM8[*TCMHAA(QCZ^IJ>O1I4^2-COA'EC8****U+"BBB M@ HHHH *1E5U*LH93U!'!I:* ,N[\/Z;=@Y@$3=FB^7'X=/TKF-2\,W=B#)# M_I$(Y)4?,OU'^%=W17/4PU.?2S(E3C(\IS17::[X=2Z5[JS4)/U9!T?_ /\ MZXL@@D$$$=0:\VK1E3=FQ_I M_P#KKA*NZ3?'3]2BN.=@.' [J>O^/X5K0J.G._0TISY6>DT4@((!!!!Y!%+7 MM'6%%%% !1110 C*KJ58 JPP0>XKSK5]/.FZC)#@^6?FC/JI_P XKT:L?Q%I MOV_3BZ+F>'YDQU([C_/I7)C*/M(76Z(J1NC@J***\3E.:X4Z.1XI5D0E70AE M([$4VBERA<]*TR^34;".X7 )&'4?PL.HJW7#^&-2^QWWV>1OW,YQUZ-V/X]/ MRKN*]_#5O:TTWOU.J$N9!111704%%%% !1110 4444 ,F_U$G^Z?Y5RW@3_C MRN_^N@_E74S?ZB3_ '3_ "KEO G_ !Y7?_70?RH ZRBBB@ HHHH **** "BB MB@#S#Q-_R,=Y_O#_ -!%9-:WB;_D8[S_ 'A_Z"*R: -;PS_R,=G_ +Q_]!-> MGUYAX9_Y&.S_ -X_^@FO3Z "BBB@ HHHH **** "BBB@#R"[_P"/V?\ ZZ-_ M.H:FN_\ C]G_ .NC?SJ&@#IO _\ R&IO^O=O_0EKOZX#P/\ \AJ;_KW;_P!" M6N_H *\:KV6O&J "NL\"?\?MW_US'\ZY.NL\"?\ '[=_]5:Y_P AV^_Z[-_.O5:\JUS_ )#M]_UV M;^= &?6YX1_Y&.#_ '7_ /036'6YX1_Y&.#_ '7_ /030!Z31110!X[-_KY/ M]X_SIE/F_P!?)_O'^=,H ZGP-_R%+G_KC_[,*[RN#\#?\A2Y_P"N/_LPKO* M&3?ZB3_=/\J\=KV*;_42?[I_E7CM !77^ _]???[J?S-+O^1CG_W4_P#016'0!H:'_P A MVQ_Z[+_.O5:\JT/_ )#MC_UV7^=>JT 4=7U*/2M/DN7&6'RHO]YNPKR^[NY[ MZY>XN'+R.>2>WL/:NA\;WADU*&T!^2%-Q'^T?_K8KEZ "BG1QO-*D4:EG=@J M@=R:]'T;PU::;$KRHLUUC+.PR%/^R/ZT ZQDC\ZE.AZJ! MG^S[G_OV:]6HH \@FM+FW_U]O+%_OH5_G4->R]1@US?BK3+%=%N+M;6-)TVX M=!M/+ 'IUX/>@#SZBBB@#T_PS_R+EG_NG_T(UK5D^&?^1Q0_P"H MC_W1_*@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %>7:C=?;=0N+@DXD;[/I%W)D@B)@"/4 MC _4UYC42U9PXR6T1:*2BHY3BN+6KH&F?VGJ*HX/DQC?)[CL/Q_QK*S7>^%+ M06^CK,1\\[%C]!P/\?QH4;LWP\.>>IN #@ 4M%%;'J!1110 4444 %% M%% !1110 445D^(-4_LS3SL.+B7*Q^WJ?P_GBDW97%*2BKLYSQ3JOVN\^R1' M,,!Y_P!I^_Y=/SK I,T5QRNW=GF2FY.[%_"C\:2EJ>4FX5VOA32S;VQO95Q) M,,(#V3_Z_P#A7.Z'IAU34%1@?)C^:4^WI^/^->B #@ 5K1IZ\S.O#PO M[S%HHHKJ.L**** "BBB@ HHHH **** "BBB@ KD?%6DA#_:$"X#'$P []F_Q MKKJCGA2X@DAD&4=2K#V-9U::G&Q,X\RL>645+=6[6MU+ _+1L5/OBHJ\IQ.# M8*6DHIX_SZUCUZ-K&G MC4M.D@_Y:#YHSZ,/\X_&O.65D8JP*LIP0>H->/B:/)/39G+4CRL**2BN;E,[ MBUZ%H6I#4=.5F.9H_DD]SZ_C_C7GE:>A:E_9NHJ[-B&3Y)/IZ_A_C6^&J>RG MKLS2G.S/0Z***]HZ@HHHH **** "BBB@!DW^HD_W3_*N6\"?\>5W_P!=!_*N MIF_U$G^Z?Y5RW@3_ (\KO_KH/Y4 =91110 4444 %%%% !1110!YAXF_Y&.\ M_P!X?^@BLFM;Q-_R,=Y_O#_T$5DT :WAG_D8[/\ WC_Z":]/KR;2[T:=J4-V M4+B,D[0<9X(KJO\ A/(O^@>__?T?X4 =?17(?\)Y%_T#W_[^C_"C_A/(O^@> M_P#W]'^% '7T5R'_ GD7_0/?_OZ/\*/^$\B_P"@>_\ W]'^% '7T5R'_">1 M?] ]_P#OZ/\ "C_A/(O^@>__ ']'^% '7T5F:)K"ZS;23+"8MC[,%LYXS6G0 M!Y!=_P#'[/\ ]=&_G4-37?\ Q^S_ /71OYU#0!TW@?\ Y#4W_7NW_H2UW]-5[+7C5 !76>!/^/V[_ZYC^=!/\ C]N_ M^N8_G0!W-%%% !1110!Y)J/_ "%+O_KL_P#Z$:JU:U'_ )"EW_UV?_T(U5H MZ/P5_P AUO\ KBW\Q7H5>>^"O^0ZW_7%OYBO0J "BBB@ KRK7/\ D.WW_79O MYUZK7E6N?\AV^_Z[-_.@#/K<\(_\C'!_NO\ ^@FL.MSPC_R,<'^Z_P#Z": / M2:*** /'9O\ 7R?[Q_G3*?-_KY/]X_SIE '4^!O^0I<_]4 ,F_U$G^Z?Y5X[7L4W^HD_W3_*O': "NO\!_Z^^_W4_F:Y M"NO\!_Z^^_W4_F: .VHHHH **** /-O%W_(QS_[J?^@BL.MSQ=_R,<_^ZG_H M(K#H T-#_P"0[8_]=E_G7JM>5:'_ ,AVQ_Z[+_.O5: /,_%1)\27>1C&P#_O M@5C5T7C.V,.N&;'RSQJV?<& A\1V8?IN)_':MYY+: MXCGB.)(V#*?<5Z9I&O6>K1+L<)<8^:%CSGV]10!JT444 %U3Q'8:8C R":<=(HSDY]SVKSS4=1GU2\:YN#\QX"CHH]!0!4 MHHHH ]/\,_\ (N6?^Z?_ $(UK5D^&?\ D7+/_=/_ *$:UJ .)\>?Z^Q_W7_F M*Y"NO\>?Z^Q_W7_F*Y"@ KV*'_41_P"Z/Y5X[7L4/^HC_P!T?RH ?1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M&-XI?9X?N!_>*@?]] _TKSRO0/%G_(!D_P!]?YUY_0E<\S&/]Y\@HHHHY3DN M+7JMK#]GLX(?^><:I^0Q7E(QFO7 %%%% !1110 444 M4 %%%% ",RHA9B JC))["O-=7U)M3U!YSGRQ\L:^B_YYKK/%E^;73!;H<27! MV_\ 1U_H/QKA/K64]78X<54UY$%+245'*E>? M.;^9?W<1Q&#W;U_#^?TIA4'[ZLI_+/]*[ZO.O#SE-=M".[$?F"*]%KLPWPM';AW[H4445T&X44 M44 %%%% !7%^*]-\BZ%[&O[N8X?V?_Z_^-=I5>]M([ZSEMI/NN,9]#V-95J? MM(6(G'F5CS&BGW$$EK<202KMD1MI%1UY+B<0M%)12Y0N=UX7U+[78?9Y&S+; MX'U7M^73\JW:\XT6]-AJD,N<1D[)/]T_X=?PKT>O3PU3FA9]#LI2YHA11172 M:!1110 4444 ,F_U$G^Z?Y5RW@3_ (\KO_KH/Y5U,W^HD_W3_*N6\"?\>5W_ M -=!_*@#K**** "BBB@ HHHH **** /,/$W_ ",=Y_O#_P!!%9-=%X@TG4+C M7;J6&SGDC9AM94)!X%9O]AZK_P! ^X_[]F@#/HK0_L/5?^@?J_P#0/N/^_9H SZ*T/[#U7_H'W'_?LT?V'JO_ $#[C_OV: .L\#?\ M@NY_Z[?^RBNIKG/!]I<6>G3IRUY5_8>J_] ^X_[]F@#/KK/ G_ M !^W?_7,?SK#_L/5?^@?: .PHHHH M**** /)-1_Y"EW_UV?\ ]"-5:V+_ $;4Y-1N72QN&5I6((0\C)JO_8>J_P#0 M/N/^_9H T_!7_(=;_KBW\Q7H55QG@_3KRSU&=[FUEB4Q8!=2,G(KLZ &3?ZB3_=/\J\=KV*4$PN ,DJ:\M_ ML/5?^@?J_] ^X_P"_9KJ/!MA=VN,]: .MHHHH **** /-O%W_(QS_P"ZG_H(K#KJ/$^EW]UKLTL%I-)& M57#*A(/ K'_L/5?^@?)-(_M;3L1C_2(LM'[^H_'_ KS5T:-V1U*LIP01@@U['6% MK?AFVU8F:,^3=8^^!PWU']: /-Z.AR*T[WP_J=@3YEJ[H/XXQN7].GXUF=#@ MT 78]8U*)=J7]R%'0>8>*9-J=_<+MFO)Y%/\+2$C\JJU9M;"[O6VVUM++[JO M'YT 5JM+I]PVG27Y3;;JP0,?XB?2NITGP7AEFU-@<<^0A_F?\/SK5\364DN@ M?9K. L5==L<:] /:@#S>BM#^P]5_Z!]Q_P!^S1_8>J_] ^X_[]F@#O\ PS_R M+EG_ +I_]"-:U9GA^&6WT*UBFC:.15.Y6&".36G0!Q/CS_7V/^Z_\Q7(5W'C M*PN[R:S-M;R3!5;=L7..EJ_] ^X_P"_9KU*($0H",$** 'T444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110!D^)D+^'KH 9("G\F%><5ZM>0? M:;&>#C,D;("?<8KR@\'!ZU<-3S,G^Z>OZ_SK.2ZG9@IVGR]SJ:***D]4**** " MBBB@ HHHH **** //_%5U]HUMT!RL*A!CUZG]3^E8E274QN;N:<]9'9_S.:B MJ;'BU)\TFQ:*2BCE(N6;*UDOKR*VB^](V,^@[G\!7IUK;1VEM';PC$<:X%GA86AS=PHHHJCJ"BBB@ HHHH **** "BBB@ MHHHH **** "BBB@#C/&"]U>XF4Y0-L3Z#C]>OX MUGYKCDKNYYE65YMB_G1245/*9W-?PT ?$%MQG&X_^.FO0JX?P?#OU620CB.( MX/H20/Y9KN*Z**M$]##? %%%%;&X4444 %%%% !1110!RGB[3O+W1HY&1AAE)!'H:X<13M*ZZG'7C:5^X ME%%%<_*87"O2=&N3=Z1;3'[Q3:V?4<'^5>;5VG@Z;?I\\/=)-W7L1_\ 6-;X M;2=NYO0E[UCHZ***[SL"BBB@ HHHH 9-_J)/]T_RKEO G_'E=_\ 70?RKJ9O M]1)_NG^54&I** ($LK2,Y2U@4_[,8%3]!@444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 5YIXALS9:W<)C"2'S$XQP?_KY'X5Z M77->,=.-Q8I>1CYX.&]U/^!_F:J#M(Y<93YZ=UT.%HI,TM=/*>+<*M:?>R:? M?174?5#R/[P[C\JJT5+C<<9-.Z/6[>>.ZMXYXFW1R*&4U)7'>#=4PS:;*W7+ MPY_4?U_.NQKG::=F>]1JJI!204444C4**** "BBB@ JO?.8M/N9 <%8F;/T! MJQ534P3I-X!W@?\ ]!-)["EL>6TM-S2UK8\"XM%)12L%ST7PO$(M MR!@N69 MO?DC^0%;%97AP@^'[0C^Z?\ T(UJUFMCW:7P+T"BBBF6%%%% !1110 4444 M%%%% !1110 4444 %8WB/5!I^G,B-B>8%4QV'2-ENRE11FBLN4\VX4M)3XHGFF2*,9=V"J M/4FE8:.T\'6IBTZ:X((,SX'N%_\ KDUT=065JEE90VR?=C4+GU/<_B:GK:*L MK'K4X\L4@HHHJBPHHHH **** "BBB@ KSC7HO(UR[3U??_WT,_UKT>O/?$W_ M ",%S_P#_P!!%8UU=(Y\3\!DT4E+7+RG#<*ZOP6WSWJ^H0_SKE*ZCP6/](NS MZ(H_4U=-6FC:@_?1V%%%%=IZ 4444 %%%% #)O\ 42?[I_E7+>!/^/*[_P"N M@_E74S?ZB3_=/\JY;P)_QY7?_70?RH ZRBBB@ HHHH **** "BBB@ HKS?4] M=U2'5;R*.]E5$G=54'H QQ57_A(=7_Y_YOSH ]2HKRW_ (2'5_\ G_F_.C_A M(=7_ .?^;\Z /4J*\M_X2'5_^?\ F_.C_A(=7_Y_YOSH ]2HKRW_ (2'5_\ MG_F_.I8_%&LQ]+UC[,BG^E 'IM%<':^.+R-@+FWBE7U3*G^HKI],\1:?JA"1 M2&.8_P#+*3@GZ=C0!JT444 %%%% & WC#258J7ER#@_NZ3_A,M(_OS?]^Z\] MF_U\G^\?YTR@#TRS\3Z;?7<=M"TADD.%RF!TS6S7F'AG_D8[/_>/_H)KT^@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***H:EJ]GI46^YDPQ^[&O+- M]!0!?HK@+_QI?3DK:(ENG8XW-^O'Z5ASZE?7)S/=SR9[,YQ^5 'K1(&,D#/ MI:\:IR2/&4P:WJ=L?W5].,=F;X-.HH M\MU?3GTO4I+9LE/O1L?XE/3_ _"J%>A^*M+^WZ:9HUS/;@L,=U[C^OX>]>> M9KKI2YHG@8JC[*I9;,6BDHK2QSW)89I+>>.:)MKQL&4^A%>HZ;?1ZE8174?& M\?,N?NMW%>55T?A'5/LE_P#8Y6_=7!POL_;\^GY5C5AI=';@J_)/E>S.]HHH MKF/:"BBB@ HHHH *CGC$UO)$>CJ5/XBI** /(3D''I15W6+::S-]HUJ[DSD>85!'H.!_*O M0-3O!8:=/!^M>8Y)Y)R:RJ:Z''BY;1"BDHK+E.*XN:ZWP4O_'Z MV/[@!_[ZKD:[OPA 8]':4CF60D'U X_F#507O(Z,,KU#?HHHKH/1"BBB@ HH MHH 9-_J)/]T_RKEO G_'E=_]=!_*NIF_U$G^Z?Y5RW@3_CRN_P#KH/Y4 =91 M110 4444 %%%% !1110!Y/J__(:O_P#KXD_]"-4JNZO_ ,AJ_P#^OB3_ -"- M4J "BM#1M,_M;4!:^=Y65+;MN[I[9%=%_P (%_U$O_('_P!E0!QM%=E_P@7_ M %$O_('_ -E1_P (%_U$O_('_P!E0!QM%=E_P@7'&I?^0/\ [*J-WX+U&!2T M#Q7 '93M;\C_ (T =TL+Y M]TAXBE/5O8^_O77UXV"58,I((.01VKU31+_^TM(@N6_UA&U_]X<'_'\: -"B MBB@#QV;_ %\G^\?YTRO63I&FDY.GVA)_Z8K_ (4G]D:9_P! ZT_[\+_A0!Y[ MX9_Y&.S_ -X_^@FO3ZJQ:;802+)%96TRCI_GWJC0 45)!!+=3I#!&9)'.%4 M=Z["P\#KL#W]RVX_\LX>WXG_ H XNBO2%\(:.!@PR-[F0U!-X*TR0?NWGB/ M;# C]10!Y]1737W@J^MP7M9$N5'\/W6_+I^M<[-#+;RM%-&T>PL[F3S)[2"5\8W21ACC\: /(J*]8_LC3/^@=:?\ ?A?\*/[(TS_H M'6G_ 'X7_"@"33O^07:?]<4_]!%6:155%"JH55& , "EH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ KS;Q+I7]F:FWEKBWFR\?H/4?A_(BO2:S-=TP:K MIDD( \Y?GB/^T.WX]*TISY97.;%T?:T[+=;'F%%!!4D$8(X(-)7H6/GKBTH) M4Y!P1T(IM%+E'<]/T'5!JNF)*Q'G)\DH]_7\>M:E>:^&]5_LS5%,C8MYODDS MV]#^'\LUZ57!4AR2L>_A*_M:=WNMPHHHK,Z@HHHH **** .(\:V?EWL-XJ_+ M*NQL?WA_]8_I7+5Z?KNG_P!I:3- HS(/GC_WA_CR/QKS#O731=U8\7'4^2IS M=&%+245K8X[CE8HZNC%64Y!!Y!KTO0]575M/60D"9/EE4=CZ_0UYE5S3-2GT MN\6XA.>S*3PP]*RJ4[K0Z<-B/92UV9ZI15+3=4MM5MO.MVY'WD/WE/O5VN8] MR,E)704444#"BBB@ HHHH **** "BBB@!"0!DG '4UYQK^K'5-0)0_Z/%\L0 M]?4_C_A71>+=6^S6WV"%L2S#]X0?NIZ?C_+-I>B-*<7.2BCH_#&D_8+'[1*N+B< M9.1RJ]A_7_\ 56]114'MP@H144%%%%!04444 %%%% !1110 445R_B'Q(L"M M9V+@RGB25>B>P]_Y?7HFR*E2,%>1G>*M6%W4\F=1SES,6C-)12Y2+C@,G &2>E>H:=:BRTZWM\ZN MCL,Q0?O&^O8?G_(UZ%3BM;GH82.CD%%%%6=@4444 %%%% #)O]1)_NG^5BS9'X@?X5P==[X'B*Z5/*?X MYL#\ /\ &@#J**** ,F;Q-I$$\D,MWMDC8JP\MS@@X/:F?\ "5Z)_P _O_D) M_P#"N U?_D-7_P#U\2?^A&J5 'JEGKVFZA<""UN?,E()V^6PX'U%:->=>#?^ M1@3_ *YM7HM !1110 45GZKK%KI$'F7#9=ON1K]YO_K>]<#JOB._U0E2YA@/ M2*,X'XGO0!W=YXATNQ)66[0N/X8_F/Z=*R9?'-DI_=6L[^[87^IK@Z* .V'C MR'/-@X'M(/\ "K4'C;39"!+'/%[E01^AS^E>?T4 >MV>I65^N;6YCE[D \C\ M.M6J\<1VC<.C%6!R&4X(KI](\8W%NRQ:AF>'IY@^^O\ C_.@#O**C@N(KJ!9 MH)%DC<9#*:DH *S?$$QM]!O9 <'RRN?KQ_6M*L?Q2I;PW> >BG\F!H \RHHH MH [GP18HMG-?,N9';RU/HHQG\S_*NLKEO!%VCZ=-:EAYD4FX#_9/_P!?-=30 M 4444 %5+_3+34X?+NH5?'W6Z,OT-6Z* .'/@F9=4C02A[(G+/G# >F/7WKM MHXTBB6.-0J( JJ.@%.HH **** "BBJU]?6VG6S3W,@1!T]2?0#N: +-4+W6M M.T\D7-TBN/X!\S?D*XG5O%E[?EH[R^.+!3B*WN)/ M<@*/YU!_PGD6>;!_^_H_PKB:* .^B\<:>QQ+;W$?N "/YUKV6MZ=J!"V]TC. M?X&^5OR->544 >RT5YYH_BR[L&6*[+7%OTY/SK]#W^AKO+2[@OK=9[:021MT M([>Q]#0!/5&_UBPTQT2\G\MG&5&QCD?@*O5PWCO_ (_;3_KF?YT =!_PE>B? M\_O_ )"?_"C_ (2O1/\ G]_\A/\ X5YG10![+1110 4453U+4[;2K8SW+X'1 M5'WF/H* +E95YXDTJQ)62Z#N/X(AN/Z<5P^K>)+W5&9-YAM^T2'K]3WK'H [ MJ3QU: GRK.9O]XA?\:8OCN#/S6,@'M(#_2N(HH ]%MO&.E3D+(TL!_Z:)Q^F M:W(+B&YB$D$J2H>C(V17CU6+.^NM/F$MK,T;=\'@_4=Z /7:*P- \31:KBWG M BNP.@^Z_P!/?VK?H **** ,=_%&C1NR->893@CRGZ_E2?\ "5Z)_P _O_D) M_P#"O.;O_C]G_P"NC?SJ&@#U6QUO3M2G:&TN/,D5=Q&QAQD#N/<5H5P'@?\ MY#4W_7LW_H2U:\0^*W,CV>G/M5>'G4\GV7V]Z .DO]<:#XEGTR189V:6S)P5/)3W'^%>BQ MR)-$LD;!D<95AT(H =1110 445G:OK5KH\.Z8[I6'R1+U;_ >] &C63=^)-* MLR5>Z5W'\,0W?RXKA=4\07^J,1))Y'?ZUVB M.LB*Z,&5AD,#D$4 .HHHH *9++'#&9)9%C0=68X K&UWQ)!I ,,8$MT1PF>% M]V_PK@;_ %.\U*7?=3,_/"]%7Z"@#O+KQ?I-N2J223L/^>2\?F<5GMX[@!^2 MQD(]W KB** .YC\=6I/[RSF4?[+!O\*U+3Q1I-X0HN?*<_PRC;^O3]:\RHH M]D!! (((/((I:\NTK7[W27 C?S(,\PN?E_#T->AZ7JUMJUKYUNV".'0]5- % MZBBB@ HHKD?$7BHV\CV6GL/,7B2;KM/H/?WH Z2\U&SL%W75S'%Z GD_0=:Q MIO&NEQG$:7$ONJ #]37G\DDDTC22NSNQR68Y)IM '=CQU9Y.;2<#M@BK4/C+ M293AVFA]WC_PS7G5% 'KEK?VEZ,VUS%+ZA6R1]15FO&U9D8,C%6'((."*Z'3 M/%]]9D)<_P"E0_[1^I6$UK)P''!_NGL?SKR MF>&2VN)()5VR1L58>XKOPT^:/*^AX.84/9U.=;/\QE%)1738X+B_2O0_">J_ M;]-^SR-F>W 4_P"TO8_T_P#UUYW5_2-2?2]2BN5R5!VR*/XE/4?U^HK"M2YX MZ;G5A*_LJEWL]SU6BFQR)+$LD;!DE.KSCZ,**** "BBB@ KS_ ,6Z M2;*_^UQK^XN#DX'W7[C\>OYUZ!5>^LH=0LY+:<91QU[@]B/>KA+EE5;LP[$55KO5FKH^>DG%V8N:*2BBPKD]K=SVJ#*GZCJ/UKB**SG24MS>CB9TOA9ZW M;7MK>+NMKB.48R=C D?4=JGKQX$@Y!.15I-3OXUVQWMPB^BRL!_.L7AWW.^. M9+[43U>BO*O[7U+_ *"%W_W^;_&C^U]2_P"@A=_]_F_QI>P? M3MJ%[(V7O+ACZF4G^M)]MN_^?F;_ +^&E["0O[1C_*>LT5Y*;VZ(P;F8C_?- M,\Z7_GH__?1H]C(/[1C_ "GKM5K^]BT^RENI3\J#@?WCV%>5^=+_ ,]7_P"^ MC2-([_>8GZFE[&0GF.FD26[NI;VZDN9CF21LGV]OI4-)FEK;EL>6ZN([>%=TDC845Z=IMA'IMC';1\[1\S8^\W2/.]V%%9>O:J-*TYI%(\^3Y8A[^OT'^%>=F] MNR3%HI,T46)N+2@$G &2>@IM=5X4T4R2+J-PO[M#^Y4C[Q_O?A_/Z5 M+5C2E!U)3YY/8^GX?XUJ444CV8Q459!11104%%%% !11 M10 R;_42?[I_E7+>!/\ CRN_^N@_E74S?ZB3_=/\JY;P)_QY7?\ UT'\J .L MHHHH **** "BBB@ HHHH \GU?_D-7_\ U\2?^A&J57=7_P"0U?\ _7Q)_P"A M&J5 '0>#?^1@3_KFU>BUY)87\^FW0N+M618XU+.Y"JHZDFO5M)L1INEP6HQN1?F([L>3^ MM8WAOPS_ &>1>7@!NM %*[NY[Z MY>XN)"\CGDG^0]J@HJ2""6YG2"%"\CG"J.YH CJ[;:1J%XNZWLYG4]&VX!_$ M\5V^C>%;6P19;I5N+GKR,JOT']:Z&@#S!O#6L*N38O\ @RG^M9T]M/:OLGAD MB;T=2#^M>P5%<6T%W"8KB))8S_"PS0!X_172^(?##:3'_B*Y MJ@#8T'7)='NL$EK5S^\3^H]Z]*BE2>))8F#1N RL.A%>.UV?@K52=^F2MT!> M'/ZC^OYT =E5;4+;[9IUQ;=Y(V4?7''ZU9HH \;92K%6!# X(/:DKJ?%VAO; MW+:C;H3!*OT/\ZY:@">SO)["Y6XMI"DB]QW]C[5VNG>-;6952_C,$ MG=U&Y#_4?K7!T4 >OV]Y;7:;[>>.5?\ 88'%35XXCO&P9&96'0J<&M6V\3:O M:X NVD4=I1N_4\_K0!Z=17&6GCH\+>V8]WA/]#_C70V.O:;J!"P7*^8?^6;_ M "M^1Z_A0!I4444 %%%% $%Y=PV-I)'_ FGEI=ZDFXL,I > M@]V_PH Y6UTZ]O?^/:UEE'JJG'Y]*N'PSK(&?L+_ /?2_P"->FHBQH$10J@8 M"J, 4Z@#R*YL;JS.+FWEBSTWJ0#5>O8I(XYHVCE171N"K#(-.6@_P#B?\* .-KJO!<-^;QY8F*V>,2[APQ[ >_O65H>B3:O=[<%($/[U_3V M'O7I=M;16ENEO @2-!A5% $M<-X[_P"/VT_ZYG^==S7#>._^/VT_ZYG^= ') MT444 >RT444 5[V\AL+.2YG;$<8R??T KR_5-3GU6]:XF/7A$SP@]!6[XTU, MS7BZ?&W[N'YGQW8_X#^=F:'H4&D6X^57NF'[R7^@]!0!QUMX0U:X4,T<<(/_/5\'\AFI)?!6JQKE6MY M3Z(YS^H%>AT4 >0W5GJGU![& MO,]8TN72+]K>0[D/S1O_ 'E_QH HH[1NKHQ5E.00<$&O2?#>M#5K'$A'VF+B M0>OHU>:5I:%J)TS5H9]V(R=DG^Z>OY=?PH ]3HHHH \@N_\ C]G_ .NC?SJ& MIKO_ (_9_P#KHW\ZAH L6MY-9B;R6VF:,Q,1U )!./RJO17;^'O"L2PI>:C' MOD8;DA8<*/<=S[4 VZ[IK.XC7U>(@?J*];5 M0JA5 "C@ #I2T >-45Z#K_AB"]A>XLXUCNE&=JC D]OK[UY\00<$8(H *[;P M3J;/'+ITC9V#?%GT[C\^?Q-<36GX>N#;:]9OG :0(?HW']: /4J**"0!DG % M &;K>KQ:/8F9@&E;B),_>/\ @*\RN;F:\N'GN)"\CG))J[KVJ-JNJ22@GR4^ M2(?[([_CUK,H **?#%)/,D,2%Y'.U5'ZZ\C*I]!_6@# MB;;1]1O%#06C;< _B:G?PUK"#)L9/P(/\C7J%% 'CTT$UM)Y<\3Q/_== M2#^M1UZ]=6=O>PF&YA65#V8=/IZ5P>O^%Y=-#7-KNEM>I'\4?U]1[T <[7>^ M#(+^.Q9YVQ:/S"C#G/MC2++$9!NI?4=1^7/X5VU &/XEU,Z;I#M&<32GR MXR.V>I_ ?TKS*NO\=R$SV47\(5F_,C_"N0H *UM/\-ZEJ,8EBA"1'H\IV@_3 MO4.AVT=WK=I!,,QL_P P]<@P* //F\$:HJY$MJQ] [?U%9MWH&J60 M+362[N8[>%=TDC!5%>EZCX>T[4@3)"(Y3_P M M8^&_'U_&J.@^&/[)OIKB659B!MA(&, ]21Z]OSH VM/LH].L8;6+[L:XSZGN M?Q-%6:* "BBB@ HHHH *XSQKI7W=3B7T2;'Z'^GY5V=1W$$=S;R02KNCD4JP M]C5TYN$E)&.(HJM3<&>/459U*QDTW4)K63JAX;^\.QJK7L*TE='RTDXMQ>XM M&:2BBPKG<^"]6\V!M-E;YX_FBSW7N/P_K[5UM>06=W+8WD5U"<21MN'OZCZ' MI7K%E=Q7UG%=0G,H_"O-Q-+DE=;,]_+L1[2'(]U^1/1117,>B%%%% M!1110!FZSH\&L6GER?+*O,<@ZJ?\*\VO;*?3[I[>XC*R+^1'J/:O6ZHZGI5K MJUOY5PG(^XX^\I]O\*VI57!V>QQ8O"*LN:.DCRJBM35M!O-(?,B^9 3\LRCC M\?0UE5WQ:DKH\.<90ERR5F+124M.Q-PI:2BE8+BT4E%*P[BTM-HI6'<=1FDH MI6"XM%)12L.XZBFTN:5@N+6GH.E-JVHK&0?(3YI6]O3ZFLQ%:1U1%+,QPH Y M)KTW0]+72M.6(@&9_FE8=SZ?05C5ERJQUX2C[6=WLC25510J@*H& , "AW6 M-&=V"JHR23P!2URGC#5_+B&FPM\[C=,1V7L/Q_E]:YHQ;=D>S5J*E!R9SFN: MJVJZBTV2(5^6)3V7U^IZUG4E%=BA961\_*;G)R?46BDHHL*XM%)1FE8+B_C1 M112L.XM%)12Y0N+1244N4=Q?QHI55G8*BEF8X R2:ZS1?"3,5N-2&%ZK!GD M_P"]_A42:1K2ISJNT2CX?\//J,BW%R"EHI^AD]A[>_\ D=\JJB!$4*JC & M!0JJBA5 50, 8 %+6+U/8HT8THV04444&P4444 %%%% !1110 R;_42?[I_ ME7+>!/\ CRN_^N@_E74S?ZB3_=/\JY;P)_QY7?\ UT'\J .LHHHH **** "B MBB@ HHHH \GU?_D-7_\ U\2?^A&J57=7_P"0U?\ _7Q)_P"A&J5 !16AHVF? MVMJ M?.\K*EMVW=T]LBNB_X0+_J)?^0/_LJ .-HKLO\ A O^HE_Y _\ LJ/^ M$"_ZB7_D#_[*@#C:*[+_ (0+_J)?^0/_ +*HI/ EP ?*OHF/;(7:1=-O'W9XA=CS_NG^E '9T444 > M3ZO_ ,AJ_P#^OB3_ -"-4JNZO_R&K_\ Z^)/_0C5*@#H/!O_ ","?]9UVOCR4B*RASPS.Q'TP M!_,UQ5 !7;^"M,5+=]1D7+N2D6>P'4_B>/PKB*]:TJ 6VDVD(&-L2Y^N.?UH M MT444 %%%% ",JNC(ZAE88(/0BO+==TW^RM5DMUSY1^>,G^Z?\ #D?A7J=< MAX[MP8+2Y ^8,8R?7(R/Y'\Z .)JQ8736-_!H 1T61&1U#*PP01D$5Q^K^#-S--IC 9Y,# MG_T$_P!#^==C10!Y!PS00W$9CGB21#U5U!%8=W MX.TNYRT2R6['_GFV1^1_IB@#SJBNJN? UVF3;744H]'!4_UK&NM"U.SR9K.7 M:/XD&X?F* ,ZBBB@#C ]5/ MH17DM:&C:K+I%^LZ$F,\2)_>7_&@#U6H;JX6UM)KA_NQ(7/X"GQ2I/"DL;!H MW4,I'<&LGQ7*8O#EU@X+;5_-AG]* /-I9'FF>60Y=V+,?4FF444 =!X2TM;_ M %3SI5S#;@,0>A;L/YG\*]%KG?!< BT/S._^/VT_ZYG^==S7#>._^/VT_P"N9_G0 M!R=%%% 'LM-DD6*)Y'.%12Q/L*=6=K\GE:#>MG&8BOY\?UH \PN9WNKJ6XD^ M_(Y<_B:BHHH ZSP18"6ZFOG&1$-B?[QZG\OYUW->U:'_">2_P#0/3_OZ?\ "@#MJ*XG_A/)?^@>G_?T_P"%'_">2_\ 0/3_ M +^G_"@#MJYWQE8BYT?[0!^\MV# _P"R>"/Y'\*R_P#A/)?^@>G_ ']/^%0W MGC-[RRGMFL4 E0IGS.F1UZ4 /Z5HUS7@F4 MOHLB'^"8@?0@'_&NEH \@N_^/V?_ *Z-_.H:FN_^/V?_ *Z-_.H: -3P]9K? M:Y;1.,QAM[#U YKU&O/_ 0H.N2$_P -NQ'_ 'TM>@4 %%%% !7F7BBT6TU^ MX"#"R8D ^O7]./^0W#[VZ_P#H34 OUC^)[PV>@W#*OZ9K8KD?'"#2T4 (JJB*B*%51@ # I:** ,3Q7=FUT"8*<-,1$/QZ_H#7F MM=MX[D(M[*+^\[-^0'^-<30 5Z3X4L!9Z)'(1^\N/WC'V_A_3^=>;5UD7CAX M84B73TVHH4?O?3\* .YHKB?^$\E_Z!Z?]_3_ (4?\)Y+_P! ]/\ OZ?\* .V MHKB?^$\E_P"@>G_?T_X4?\)Y+_T#T_[^G_"@"MXUL1;ZI'=(,+<+S_O#@_IB MN9K;UOQ$=:@BC:U6(QMN#!\]NG2L2@"YI=U]BU6UN,X"2 M].A_3->LUXU7K MUC+YVGVTI.=\2M^8% ')>.X6WV"/Z_E7'5ZKK.F+JVFR6Q(#_> MC8]F'3_#\:\NN+>6UG>"="DB'#*>U "12R02I+$Q61"&5AV-=SI7C*VG18]0 M'D2]/, RC?X5P=% 'L44T4\8DAD21#T9&!%/KR"WNKBU??;S21-ZHQ%;MEXS MU&WPMPL=RH_O#:WYC_"@#T*BL33O%6FWY",YMY3QMEX!^AZ5MT %%%% !111 M0 4444 %%%% ',>,M)^UV OHES-;CYL=T[_EU_.O/Z]F(#*58 @C!![UY9K^ MEG2=5DA /DO\\1_V3V_#I7H8.K?]VSQ,TP]G[:/S,S-%)17?8\>XZNL\%ZMY M-PVG2M\DIW1$]F[C\1_+WKD:?'(\4J21L5=&#*PZ@BLJM)5(.)OAZ[HU%-'L MM%4-&U)-5TR*Z7 8C;(H_A8=?\?QJ_7C--.S/JHR4HJ2V84444B@HHHH *** M* $95=2KJ&4C!!&0:YK4_!MI6WV@ZEI^3-;,T8_Y:1_,OZ=/QQ6;7LE4KK2=/O[_[[7_XF@>"-,_Y[79_X&O_ ,32>(IC_L^OY' T5UFN>'])TC3V MF\VY,S?+$A=>3^705R5:4YJHKHYJU*5&7++<6BDHJ[&5Q:6DJYI6G2:IJ$=K M'D;CEV_NKW-3*R5V7%.344=#X.T?S9?[2G7Y$.(01U;N?P_G]*[:HX(([:WC M@A4+'&H50/2I*\VJ:A'IEA)=2<[1A5S]YNPKRZXN);JXD MGF;=)(Q9C[UZ/K&AIK+1^;]W_W MVO\ \31_PA.F_P#/>[_[[7_XFE[6 _J-8X2BN\_X0G3?^>]W_P!]K_\ $T?\ M(3IO_/>[_P"^U_\ B:7M8!]1K'!T5WJ^"],!YDN6^KC_ J[!X9TB JPLU=A MWD8MG\"<5+K1Z(N. JO>QYS%#+/($AB>1S_"BDFMZP\(7]SAKDK;1^A^9OR' M]:[N*&*!-D,21I_=10!^E/K.55O8Z:> @M9NYG:;HECI8S!%F3',K\L?\/PK M1HHK,[HQ459(****!A1110 4444 %%%% !1110 R;_42?[I_E7+>!/\ CRN_ M^N@_E74S?ZB3_=/\JY;P)_QY7?\ UT'\J .LHHHH **** "BBB@ HHHH \GU M?_D-7_\ U\2?^A&J57=7_P"0U?\ _7Q)_P"A&J5 '0>#?^1@3_KFU>BUYUX- M_P"1@3_KFU>BT %%%% !1110 5P/B_1H[&>.\MD"0S':R <*W7CZ_P!*[ZN> M\:%?[!^;J95V_7G^F: /.Z:?;W(_P"6L88C MT..:L5C^%F+>&[,GT8?^/FMB@#R?5_\ D-7_ /U\2?\ H1JE5W5_^0U?_P#7 MQ)_Z$:I4 =!X-_Y&!/\ KFU>BUYUX-_Y&!/^N;5Z+0!Q7CP'S;$]BKC_ -!K MCZ[SQS;E]-MYP,^5+M/L"/\ ZPK@Z "O8+9P]K"XZ,@(_*O'Z],\+WHO-"@& M?GA'E,/3'3],4 ;-%%% !1110 5S'CEA_8\"]S< _P#CK?XUT]<-XXO!)>6] MFI_U2EV^IZ?H/UH Y.BBE4%F"J,DG H ]2\/@KH%D#_ ,\@:TJAM(/LUE! M/^64:I^0Q4U !14-Q=06H0W$R1AVVJ6.,GTJ:@ HHHH **** ,[4-#T_4@3/ M;J)#_P M$^5OS[_C7!ZYX?GT9P^[S;9SA9,=#Z'WKTVL_78%N-#O48 XB9A] M0,C^5 'E5%%% 'HO@ZZ-QH8C8Y,$A0?3J/Y_I2^,03X>D([2*3^=4/ A/V6\ M&/EWKC\C6WX@MS1@9(CWC_@)W?TH \MHHHH ]*\).&\-VP'\)<'_ +Z) M_K6W7(>!KT&"XLF/S*WFJ/4'@_R'YUU] !1110 4444 %%%% !7#>._^/VT_ MZYG^==S7#>._^/VT_P"N9_G0!R=%%% 'LM97B4$^';P#^X#^HK5JIJE?] ^W_P"_8H_L/2O^@?;_ /?L M4 8W@;_D%W/_ %V_]E%=34-M:6]G&8[:%(D)W%4&!FIJ /(+O_C]G_ZZ-_.H M:FN_^/V?_KHW\ZAH Z;P/_R&IO\ KW;_ -"6N_K@/ __ "&IO^O=O_0EKOZ M"BBB@ K@/''_ "&H?^O=?_0FKOZX#QQ_R&H?^O=?_0FH YFIK3_C]@_ZZ+_. MH:FM/^/V#_KHO\Z /7ZXWQZ#C3SCC]Y_[+795S'C>W,FE0S@?ZJ7GZ$?XXH MX&BBB@#UZQ8-I]LRG(,2D?D*GK%\*WHN]"A7.7A_=,/IT_3%;5 !1110 444 M4 %%%% '&^/0<:><Z']:T5ZK_ &'I7_0/M_\ OV*/[#TK_H'V_P#W M[% 'E5%>J_V'I7_0/M_^_8H_L/2O^@?;_P#?L4 >545ZK_8>E?\ 0/M_^_8H M_L/2O^@?;_\ ?L4 >55ZQI'_ "!;#_KWC_\ 013/[#TK_H'V_P#W[%7T18T5 M$4*JC ["@!:S-7T*TUB/]Z"DRC"RKU'L?45IT4 >:ZAX6U.Q)98OM$0Z/%R M?Q'6L4@J2""".H->R55NM.L[X8N;:*7W9>1^/6@#R2BN]O/!%E+EK2:2!NRG MYU_Q_6N9U+PWJ.F*TDD8EA'62/D#Z]Q0!D5OZ%XFN-,=8;AFEM.FT\E/I_A6 M!10![%%+'/"DL3!XW&Y6'<45Q?A37$M+.:VN6.Q&!C]LYR/\^M% ';T444 % M%%% !1110 5B^)])_M72F\M-<6]R2PQT5NX_K^/M7/U[M.:J04D?(UJ$M6_L_4Q!(V(+DA3GLW8_T_&O1Z\6KT_P ,:M_:NE+YC9N(<)+GJ?1O MQ_GFO,QM&S]HCW,JQ-U[&7R-JBBBN ]D**** "BBB@ HHHH **** "BBB@ H MHHH *1F5%+,0% R23P!2UR?C+6?(@&FP-^\E&92#T7T_'^7UJH0O&"BK(^7G4E.3E+=BTM-HIV) MN.KT?POH_P#9FG^;*N+FW.>1PS]A^'7\ MO6O0ZX,54N^1'LY;A]/:R^04445R'K!1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 R;_42?[I_E7+>!/^/*[_ M .N@_E74S?ZB3_=/\JY;P)_QY7?_ %T'\J .LHHHH **** "BBB@ HHHH \G MU?\ Y#5__P!?$G_H1JE5W5_^0U?_ /7Q)_Z$:I4 =!X-_P"1@3_KFU>BUY3I M&IG2;\72Q"0A2NTMCK70?\)Y+_T#T_[^G_"@#MJ*XG_A/)?^@>G_ ']/^%'_ M GDO_0/3_OZ?\* .VHKB?\ A/)?^@>G_?T_X5%)XZO"#Y5I OIN);_"@#NR M0!DG %>?^+=:CU"X2UMG#P0G)<=&;V]A_6LR_P!>U'4E*3W!\L_\LT&U?TZ_ MC6;0 445H:+IKZKJ<5N ?+!W2'T4=?\ "@#T/P_ ;?0+*,C!\O<1_O<_UK2I M H P!P *6@#R?5_P#D-7__ %\2?^A&J57=7_Y#5_\ ]?$G_H1JE0!T'@W_ M )&!/^N;5Z+7G7@W_D8$_P"N;5Z+0!4U2R&H:9<6IZR)\I]&ZC]<5Y.Z-&[( MX*LIP0>QKV.N&\8:*89CJ4"_NY#B8 ?=;U^A_G]: .3K7\/:R=(O]SY-O+\L MH';T/X5D44 >Q12QSQ++$X>-QE64\$4^O+](\07FD';&1) 3DQ/T_#T-==:^ M,M+F4>>9+=NX92P_,4 =%160?$^C 9^W+^",?Z5EWWC>VC4K8PO*_9I!M4?A MU/Z4 ;NJZI!I-FT\QRW1$SRY]*\NNKF6\NI+B9MTDC;F-/OK^YU&X,]U*7?M MZ*/0#M5:@ K;\*Z>;[6HW(S%;_O&/N.@_/\ E6-'&\LBQQJ6=CA5 Y)KT_0= M)72-.6(X,S_-*P]?3Z"@#4J*YN8K2VDN)W"1H,L34M<+XUN+XW:021E+,V' .?F0>WJ/: MN/V]U/:2B6WE>*0?Q*<5T=GXWO8@%NH M([@#^(?(W^'Z4 =[17,1>.-/8#S;>X0^P!'\ZD/C;2P,[+D^VP?XT ='6'XJ MU*.RT>6'I^F*R+SQT2I6RM,$]'E/3\!_C7)W5W/?7#3W,K22- MU)H AHHJ6WMY+JXC@A7=)(P51[T =WX)@,>CR2D?ZV4D?0 #^>:Z0@,"",@\ M$&H+"T2PL8;6/E8E"Y]3W/YU8H \GU6Q;3=3GM6!PK?(?53T/Y52KT'Q;HQO M[07<"YN(!R!U9/\ $=?SKSZ@"UIU_+IM_%=1?>0\K_>'<5ZE87T&HVB7-N^Y M&ZCNI]#[UY'5W3=5N]*G\VUDQG[R'E6^HH ]8HKF++QM8RJ!=QO _<@;E_3G M]*T/^$GT;&?MR_\ ?#?X4 :]1SSQ6T+332+'&@RS,>!7/7GC73H5(MDDN'[< M;5_,\_I7'ZIK5YJTFZXDQ&#E8EX5?_KT =II_BVTOM2>U*F)&.(9&/W_ *^G MM70UXU7:^&/$QD9+"_@#L*X;QW_Q^VG_ %S/\Z[FN&\= M_P#'[:?]%_P"%>GHZR1K( MC!D895@>"*\GZU=_M*PQG[;;?]_5_P : +5%9%UXFTFU4DW:RMV6'Y\_B./UKDM8\676 MHJT%N#;VYX.#\S#W/]!0!V,.O:=/J36"3@RCHW\+'T![FM.O&P2"""01R"*[ M;PYXI\XI9:@_[P_+',?XO9O?WH ZZBBB@#R"[_X_9_\ KHW\ZAJ:[_X_9_\ MKHW\ZAH Z;P/_P AJ;_KW;_T):[^N \#_P#(:F_Z]V_]"6N_H **** "N \< M?\AJ'_KW7_T)J[^N \M?&6ESJ/.,ENW<,I M8?F*M'Q/HRC)OE_!&/\ 2@#7JIJ.I6VEVIGN7VC^%1U8^@%<]?\ C>W1"MC" MTC]GD&%'X=3^E<=>WUSJ%P9KJ5I'/3/0#T [4 >A:'XC@U@O$RB&X4DB,G.Y M?4?UK;KQV*62"598G*2('(_4"O)V4JQ5@0P."#VKV2N!\8:.;6[^WPK^YF/SX_A?_ .O_ M #S0!S%=AX,U=8RVFSMC>=T)/KW7^OYUQ]*"0002".010![)17$:1XS:)%AU M)6D4<"9?O?B._P!:Z>#7=+N5!COH.>SMM/Y&@#0HJHVJ:>B[FOK8#WE7_&LJ M^\7Z;:J1 QN9.RH,#\2?Z9H W)YXK:%IIY%CC099F/ JKIFKVFK1,]LY)4X9 M&&&'OCTKSG5=:O-7ES.^(U/R1+]T?XGWJK9WD]AX[^Q]J /7J*R M-"UZ'682,".Y09DC_J/:M>@"&ZN8K.UDN)FVQQKN8U6TO6+/5H=]O)\X'S1M MPR_Y]:Y'QAK/VJY_L^!OW,)_>$?Q/Z?A_.N:BED@E66)V213D,IP10![%17" M:=XVN80$OHA.H_Y:)\K?ET/Z5T=KXHTBZ _TH1,?X91MQ^/3]: -BCJ,&JHU M*P(R+VV(/_35?\:H7_BC3+*-BLZW$F/E2([L_CT% '$^);.&QUR>* !8SAPH M_AR.E9-6+Z\EO[V6ZF^_(V2/3T'X"J] !172^%M%34H;F6881655/J><_P!* M* /0**** "BBB@ HHHH **** ,_6M,35M+EM6P'(W1L?X6'3_#Z&O)Y(WAE> M.12KH2K*>H(ZBO:*X+QOI'D7*ZE$N(Y3ME '1NQ_$?R]Z[\#6Y9U A@"""#R"*6N8\&:O\ ;+ V,K9FMQ\N>Z=ORZ?E73U\_4@X2<7T M/L*%6-:FIQZA1114&H4444 %%%% !1110 4444 %%%% %34]0BTS3Y;J7D(/ ME7/WF["O*+FYEO+J2XF;=)(VYC6WXLUG^TM0^SPOFV@.!@\,W<_T'_UZYZO5 MPE'DCS/=GSF88KVM3DCLOS%HI**ZK'GW'5-:6LM]=Q6T"[I)&P/\?I5>N_\ M!NC?9;7^T)U_?3#]V"/NIZ_C_+'K6%>HJ<+]3JPM!UZBCTZF_I]C%IUC%:PC MY4')_O'N?QJU117CMW/J$E%604444#"BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DW^HD_W3_*N6\"?\>5W_ M -=!_*NIF_U$G^Z?Y5RW@3_CRN_^N@_E0!UE%%% !1110 4444 %%%% 'D^K M_P#(:O\ _KXD_P#0C5*NCU'PSJ\^J7J3^7;1$@'YG/"K]37H^CZ1!H]IY47S2-S)(1RQ_P]JO10Q01B.&-(XUZ M*@P!3Z "BBB@#R?5_P#D-7__ %\2?^A&J5='J/AG5Y]4NYHK3='),[*?,09! M8D=ZJ_\ "*:W_P ^7_D5/\: )_!O_(P)_P!7$$8 M;O,4\GZ&NTH *;)&DL;1R*&1AAE(R"*=10!YYK_AB736:XM0TMIU/=H_K[>] M<[7LM<]JGA&ROBTMN?LTQY.T94GZ=OPH \[HK:O/"NJVA)$'GH/XH3G].OZ5 ME2VUQ 2)8)8R.H="* (J*4 DX ))["K4&EW]R1Y-G.^>X0X_.@"I4D,$MS,L M,,;22,_O70T44 %17-K!>6[07$:R1MU5JEHH X#6/"%S: M%IK'=/!UV?QK_C7-$$$@@@C@@U[)6=J&AZ?J>3<0#S/^>B?*WY]_QH \KHKK MKSP-,I+6=TKC^[*,'\Q_]:L:?PWJ]N?FLI&'K'A_Y4 95%6'L;N/_66LZX_O M1D5&MO,QPL,A/LIH CHJ]#H^I3G]W8W!SW,9 _,UL67@J_F(-U)';IW&=S?I MQ^M '-HCR.J(I9V. JC))KT#PSX=_LQ/M5T ;IQ@+U\L?XUH:7H5CI(S!'NF MQ@RORQ_P_"M.@ HHHH *XWQ)X69F>]TZ/.>9(5_FO^%=E10!XT00<$8(HKTW M5?#=CJA,C+Y-P?\ EJ@Z_4=ZY&]\(:G:DF)%N8_6,\_D?Z9H P**GFL[JW.) MK::,C^^A%04 %%6(;"\N#B&UFD_W8R:VK'P=J5RP-P%MH^Y8Y;\ /ZXH P(H MI)Y5BB1GD8X55&2:[[PYX973@+J[ :Z(^5>HC_\ KUI:7HEEI*?N$W2D?-*_ M+'_ 5I4 %<-X[_X_;3_KF?YUW-_P!3NK=[.#S%1"&.]1@Y]S0!PM%; M/_"*:W_SY?\ D5/\:/\ A%-;_P"?+_R*G^- 'IE%%% !7'>)/"[.[WVGIDGF M2%1R3ZK_ (5V-% 'C1!!P1@BBO3=5\-V.JDR%3#<'_EJG?ZCO7(WOA#4[4DQ M(MS'ZQG!_(_TS0!@45/+974!Q-;31_[Z$5!0 458AL+RX.(;6:3_ '8R:VK' MP=J5R0;C9;1^K'+?D/ZXH Y]$>1U1%+.QP%49)-=YX;\,BQVWEZH-SU1.HC_ M /K_ ,JU-*T&RTEE:= !1110!Y!=_\ '[/_ -=&_G4-;USX M7UF2ZF=;/*LY(/FITS]:B_X136_^?+_R*G^- %WP/_R&IO\ KW;_ -"6N_KD M/"NB:CINJ2S7=OY<;0E0=ZGG*M$U'4M4BFM+?S(UA"D[U'.YCW/N* .)J:T_X_8/^NB_SK3_X136_^?+_ M ,BI_C4MMX7UF.ZA=K/"JX)/FITS]: /1Z*** &R1I+&T]>B4=1@T >-45Z%JG@^SO2TMJ?LTIY( RA_#M^%< MK=^%]6M"?]&,R_WH?FS^'7]* ,>BI)()H3B6*1/]Y2*8 6. "3Z"@!**N0:5 MJ%R?W-E.X/<(T_P3=2LKWTBP1]T0[F/]!^M '.V5C<:APKTC0]#AT:W(!WW#@>9)_0>U7+'3[73H!#:Q!%[GNQ]2>]6: "HYX(KF M!X)D#QN,,I[BI** /-==\.SZ3*TL8:2T)^5^Z^S?XUB5[(RJZE64,I&"",@U MS&I^#+:Y9I;%_L\AYV$90_U% '!45K77AK5K0G=:-(H_BB^?/X#G]*S9(983 MB6)T/^TI% $=%*JLQPH)/L*NV^CZE=$"&RG.>Y0@?F>* *-6K#3[G4KD06T9 M9CU/91ZDUTFG>")G8/J$PC7_ )YQG+'ZGH/UKK[.RMK" 0VL2QH.PZGW)[T M5-%T:#1[7RT^>9N9),C+N*Y&,J>1]*=10!YMK/AJ\TQFE7,]MG/ MF*.5_P!X=OK6'7LM8>H^%-.ORSHAMYC_ !1=#]1T_E0!YM171W?@O4H"3;F. MX7MM.UOR/^-9$VD:C ?WMC<+[^62/SH IT5)]GF#;3#)N]-IJQ#I6H7!Q%97 M#>_EG'YT 4ZL65E/J%VEM;IND<_@!ZGVK>L/!=].P:[=+>/N =S?IQ^M=EIN ME6FE0>5:QX)^\YY9OJ: ':;81Z;816L7(0/A_ \U8HH3MJA-)JS/&KVTEL+V:UF&)(FV MGW]_H:@KO/'&D>;;KJ<*_/%\LN!U7L?P/\_:N"KZ'#555IJ77J?'XR@\/5<. MG3T%HI**WLH2:9J,-W'DE#\R_WE[C\J]OE.*Y)^REL]O7_@G;4445Y!]&%% M%% !1110 4444 %%%% !7/>+-9_LVP^SPOBYN 0,=57N?Z#_ .M6W=7,5G:R M7,[;8XUW,:\FU/49=4U"6[EZN?E7/W5["NK"4/:SN]D>=F.*]C3Y8_$RK124 M5[5CYJXOYT4E/CC>:5(HU+.Y"JHZDFD[+4:U-?PWI!U?4U5U/V:+YI3Z^B_C M_+->G@!0 !P *SM#TI-(TR.W&#(?FE8=V/].U:5>'B*OM9WZ'U."PWL*=G MN]PHHHK [ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** &3?ZB3_=/\JY;P)_QY7?_70?RKJ9O]1)_NG^ M5]=F"K^RJ6>S/-S/"^VI2A!NI05B7T_ MVC["JC%SDHQW(J5(TX.LPPQV\*0Q*%C10JJ.P%>=CJW*O9KKN>O ME6%YY>UELMO7_@#Z***\D^B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &3?ZB3_=/\JY;P)_Q MY7?_ %T'\JZF;_42?[I_E7+>!/\ CRN_^N@_E0!UE%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y9XHTC^R=681KBWFR M\6.@]5_#^6*Q*]9\0:0NLZ6\(P)T^>)CV;T^AZ5Y0Z/'(T;J5=20RD8((KWL M%7]I3L]T?)YEA?85;KX7M_D-HHHKM/."NH\.>+'TW;:7I:2TZ*PY:/\ Q'^? M:N7HK*K2A5CRR-J%>I0GSP9[3!<0W4*S02K)&W1E.0:EKQW3]5O=+E\RTG:/ M/WEZJWU%=;8^/T("W]H0>[P'(_[Y/^->/5P%6#]W5'T6'S:C45JGNO\ [6B ML2+Q=HDJ@_;-AQRKQL"/TQ4S^)=&09.H0_AD_P JY'2FM&F=ZQ-%JZFOO1JT M5SESXVTB ?NFEN#CC8F!_P"/8KF]2\;ZA=JT=JJVD9[J=S_GV_ 5M3P=:;VM MZG/6S+#TE\5WY:G7:YXCM-&B*DB6Z(^6%3S]3Z"O,[Z_N-1NWN;ER\C?D!Z# MVJNS,[EW8LS')).2325Z^&PD:*ONSY[&8ZIB79Z1["YHIM%=5CAN.HIO-=5X M,T4WM[]OG3-O;GY ?XG_ /K=?RK*M45*#FS?#T95ZBIQZG4^%]&_LG3 95Q= M3X:3_9]%_#^=;E%%?.3FYRFX3/$:* M[KQ+X1\PO?:9'\Y^:2 =_=??VKAB""01@CJ#7T%"O"M&\3Y#$X6IAY\L_O[B M4445N5W_UT'\JZF;_ %$G M^Z?Y5RW@3_CRN_\ KH/Y4 =91110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !6!KGA:TU<--'B"[Q_K%'#?[P_K_. MM^BJA.4'S1=F9U:4*L>2:NCR#4M'OM)EV74)54;Z&J%>UR11S1M'*BN MC<%6&0?PKFM1\#Z?=$O:.UJY[#YD_+M^=>K1S%/2HOF>#B,FDM:+OY,\YHK? MO/!VKVF2D2W"#O"V3^1P:QI[2YM6VW%O+$WI(A7^==\*U.?PR/)J8>K3^.+1 M#1116ID%%%7[71=3O"/(L9V!Z,4POYGBIE.,?B=BHPE-VBKE"@9)P*ZZQ\!W MDN&O;B.!?[J?.W^ _6NLTSP]INE8:W@W2C_EK)\S?_6_#%<57,*4/AU9Z-#* MJ]36?NK^NAQVB^#+J]*S7^ZVM^NW'[QOP[?C^5=]:6=O86ZV]K$L<2] /YGU M-3T5Y5;$3K.\CZ##8.EAU[BU[A1116!U!1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 -D!:)U'4J0*P?"NEW>EVUPEW&$9W!7# \8]JZ"B@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@"L^G6,IS)96[_ .]$I_I3/[(TW_H'6G_?E?\ "BBG=DN$7T)XK:"# M_4PQQYZ[$ _E4M%%(I*VP4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D! end